Table 1.
Clinical trials evaluating checkpoint Inhibition of the CD47-SIRPα axis in multiple myeloma
| Clinical Trials.gov Identifier | Drug name | Mechanism of action | Study design and description | Current status |
|---|---|---|---|---|
| NCT04892446 | Hu5F9-G4 (magrolimab) | Human IgG4 monoclonal antibody against CD47 | Multicenter, phase II study evaluating the efficacy of magrolimab dual therapy with daratumumab, combination therapy with pomalidomide and dexamethasone, and dual therapy with carfilzomib, in patients with relapsed/refractory MM. | Ongoing |
| NCT04445701 | AO-176 | Humanized IgG2 monoclonal antibody targeting CD47 | Open-label, multi-center, dose-escalation phase I/II clinical trials evaluating efficacy of combination therapy of AO-176, dexamethasone and bortezomib in patients with relapsed/refractory MM. | Ongoing |
| NCT05139225 | Maplirpacept (TTI-622) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG4 | Open-label, phase I study evaluating TTI-622 in combination with daratumumab in patients with relapsed/refractory multiple myeloma | Ongoing |
| NCT05567887 | Maplirpacept (TTI-622) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG4 | Open-label, phase I study in patients with relapsed/refractory MM to assess safety and tolerability of Maplirpacept monotherapy | Ongoing |
| NCT05896774 | Maplirpacept (TTI-622) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG4 | Open-label, phase I study in patients with relapsed/refractory MM to evaluate safety and tolerability of Maplirpacept monotherapy. | Ongoing |
| NCT03530683 | Maplirpacept (TTI-622) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG4 | Open-label, multi-center phase I study evaluating the safety and efficacy of maplirpacept monotherapy against maplirpacept/carfilzomib/dexamethasone triple therapy and maplirpacept//carfilzomib/dexamethasone combination therapy in patients with relapsed/refractory MM. | Ongoing |
| NCT05675449 | Maplirpacept (TTI-622) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG4 | Open-label, phase Ib study comparing elranatamab/maplirpacept dual-therapy to elranatamab/carfilzomib/dexamethasone combination therapy in patients with relapsed/refractory MM. | Ongoing |
| NCT04895410 | Lemzoparlimab | Novel, differentiated CD47 antibody targeting a distinct CD47 epitope preferential to tumour cells | Phase 1b, dose escalation and exapansion study of Lemzoparlimab with or without dexamethasone and in combination with anti-myeloma regimens for the treatment of patients with relapsed/refractory MM. | |
| NCT02663518 | Ontorpacept (TTI-621) | Fusion protein of CD47-binding domain of SIRPα linked to Fc region of human IgG1 | Open-label, phase Ia/Ib trial evaluating Ontorpacept monotherapy in patients with relapsed/refractory MM. | Terminated for administrative reasons |